Dr. Stefan Bossmann
M.S., University of Saarland, Germany (1988)
Ph.D., University of Saarland, Germany (1991)
Postdoctoral Research Fellow, Columbia University (1991-3)
Professor, University of Karlsruhe (1993-2004)
Office Phone: 785-532-6817
Lab Phone: 785-532-3090 (3rd Floor)
Lab Phone: 785-532-6672 (4th Floor)
Website: Bossmann Group
Recent Awards, Honors and Donations
- “STEM Research Exemplar” by The Research Exemplar Project of the Washington University School of Medicine in St. Louis in 2017 (http://integrityprogram.org/exemplar-project/stem-exemplars/).
- Erwin W. Segebrecht Award for Excellence and Inspiration in Teaching, Research, and Service in 2017.
- Funding by NSF (EAGER with Prof. Dr. Culbertson at Kansas State in 2016), NIH (R01 with Prof. Dr. Wolschendorf, University of Alabama at Birmingham in 2016, COBRE with Department of Psychology in 2017), Anticipate Ventures, LLC (with Prof. Dr. Sorensen, Physics at Kansas State) and private donations (Eric Stonestreet).
- Cell-Mediated Delivery of Drugs to Tumors
- Image-Guided Hyperthermia of Solid Tumors
- Liquid Biopsies for Early Stage Solid Tumors
- Design of a Point-of-Care (POC) Detection Device
- Copper Activated Drugs Against Gram-positive Bacteria
- Transforming Printmaking through Chemical Innovation
Cell-Mediated Delivery of Drugs to Tumors In collaboration with Deryl L. Troyer, we have pioneered the use of stem cells and defensive cells, which actively migrate to tumors, as transport modalities to effectively target tumors and metastases.1-5We were the first team utilizing stem cells for the transport of nanoformulations to solid tumors.6 We also hold the US record for maximizing the survival times of mice bearing pancreatic tumors by means of cell-mediated hyperthermia.7 Recently, we have developed peptide-based nanosponges for the delivery of drugs, DNA, and RNA to leucocytes in peripheral blood.8 The design of the nanosponges was sparked by a CREATIVE grant from the National Science Foundation.
Image-Guided Hyperthermia of Solid TumorsIn collaboration with Deryl L. Troyer, and Punit Prakash, we have developed an integrated platform for small-animal hyperthermia investigations under ultra-high field MRI guidance.9 This platform enables us to optimize the effect of immune-stimulating hyperthermia on solid tumors and to observe the migration of defensive cell populations into tumors and metastases. Furthermore, we have optimized this technology to detect micrometastases (< 2mm in diameter). To the best of our knowledge, this is the first time when micrometastases could be detected by means of Magnetic Resonance Imaging. This was made possible by a 600MHz (14.1T) NMR/MRI from the National Science Foundation. I have summarized this endeavor in a recent presentation at the Coffman Foundation in Kansas City, as well as the approach to liquid biopsies for cancer detection
Liquid Biopsies for Early Stage Solid Tumors (Breast, Lung, Pancreatic, and Thyroid Cancers) The synthesis of tailored Fe/Fe3O4 nanoparticles, which are dispersible and sufficiently stable in aqueous buffers has enabled the design of ultrasensitive nanobiosensors for the detection of multiple proteases (ADAM’s, cathepsins, caspases, granzymes and matrix metalloproteinases), and enzymes capable of post-translational detection (multiple kinases and arginase) with sub-femtomolar limits of detection.10-12 We have developed a methodology for liquid biopsies using serum from cancer patients, which permits the detection of stage 1 breast-, lung-, and pancreatic- cancers with more than 95% accuracy. Stage 0 detection is currently being developed. The development of liquid biopsies for solid tumor detection at the earliest stages is performed in collaboration with Anup Kasi, and Stephen Williamson, University of Kansas Medical Center and with Gaohong Zhu, head of Radiology of the First Affiliated Hospital of Kunming Medical University, China, where we have carried out two successful clinical trials in 2014 to 2016, with a total of more than 15,000 patients. We were able to identify protease signatures for 11 types of solid tumors. KSURF holds the patents for this technology.
Design of a Point-of-Care (POC) Detection Device In collaboration with Dr. Christopher T Culbertson, we are developing a POC Device for simultaneous protease, kinase and cytokine detection, which is based on isoelectric focusing. This system will be characterized by potential enzyme amplification, analyte volume reduction and focused detection bands thus permitting limits of detection (LOD) improvements of 106, so that the detection of analytes at the fM and sub-fM levels becomes feasible. Additionally, the capability of multiplexing, high peak capacity and the ability to independently alter the band placement allows a large number of analytes to be analyzed. This is necessary to detect and identify the subtle changes that take place early in the progression of a disease. In collaboration with Allan Brasier and Massoud Motamedi (UTMB), we have established the company Mobile Biosensing Diagnostics LLC in 2017 as a Joint Venture of KSU and UTMB. The contract establishingMobile Biosensing Diagnostics LLC was signed in August 2017.
Copper Activated Drugs Against Gram-positive Bacteria
Copper-activated drugs against Methicillin-resistant Staphylococcus aureus (MRSA) and, potentially, other multi-resistant pathogens, increase significantly in their efficacy when forming copper(I) complexes. They are very promising in the uphill battle against infectious diseases, because they utilize copper(I), which is provided as a cellular response to bacterial infections within phagosomes.13 This strategy is part of the "nutritional immunity response", in which the host cells attempt to sequester vital nutrients of the invading pathogens, while increasing the concentration of toxic copper(I). This research is conducted in close collaboration with Assistant Prof. Dr. Frank Wolschendorf, Departments of Medicine and Microbiology, at the University of Alabama at Birmingham. We have identified a novel type of thiourea compounds with NNSN-motif.14-16 Upon complexation with Copper I, an iminium cation is formed, which is a well-known reactive intermediate in numerous org. reactions. It is our paradigm that this reactive group is capable of acting as a warhead and/or can facilitate DNA-intercalation.
Figure 6:Compounds with NNSN-motiftake advantage of nutritional immunity (from reference16)
Transforming Printmaking through Chemical Innovation In collaboration with Jason Scuilla, master printmaker and Associate Professor in the Kansas State Department of Arts. To date, most of the procedures that are being used in the arts closely resemble alchemic procedures, with little understanding of the manifold of the underlying electrochemical reactions and only modest regard for safety considerations. Since 2014, we are implementing well-established electrolytic etching processes from the semiconductor- and computer industry in Jason’s art studio. These procedures do not only provide professional safety standards in the art studio, they also allow the artist to tailor the electrochemical conditions to fine-tune artistic expressions. This approach is guided by the paradigm that the best art can be created by mastering the required technique(s).